Eton Pharmaceuticals Boosts 2026 Revenue Outlook to Over $120M on 73% Q1 Sales Jump
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals reported a substantial 73% year-over-year increase in Q1 product sales, driven by its expanded portfolio. The company also raised its full-year 2026 revenue guidance to exceed $120 million, up from its prior forecast of $110 million. This strong performance follows the recent FDA approval and launch of DESMODA and the successful relaunch of HEMANGEOL, both contributing significantly to growth. The significant sales growth and upward revision of guidance are material for the company, indicating strong operational momentum and product adoption. Investors will be watching for continued execution on new product launches and the company's ability to maintain its strong growth trajectory.
At the time of this announcement, ETON was trading at $30.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $819.7M. The 52-week trading range was $13.09 to $32.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.